Nxera Pharma Dirección

Dirección controles de criterios 2/4

El CEO de Nxera Pharma es Chris Cargill, nombrado en Mar 2022, tiene una permanencia de 2.67 años. posee directamente un 0.046% de las acciones de la empresa, con un valor de €292.67K. La antigüedad media del equipo directivo y de la junta directiva es de 2.7 años y 5.7 años, respectivamente.

Información clave

Chris Cargill

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	2.7yrs
Participación del CEO	0.05%
Permanencia media de la dirección	2.7yrs
Promedio de permanencia en la Junta Directiva	5.7yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Chris Cargill en comparación con los beneficios de Nxera Pharma?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-JP¥4b
Jun 30 2024	n/a	n/a	-JP¥10b
Mar 31 2024	n/a	n/a	-JP¥9b
Dec 31 2023	n/a	n/a	-JP¥7b
Sep 30 2023	n/a	n/a	-JP¥3b
Jun 30 2023	n/a	n/a	JP¥2b
Mar 31 2023	n/a	n/a	JP¥1b
Dec 31 2022	JP¥292m	JP¥88m	JP¥382m
Sep 30 2022	n/a	n/a	-JP¥383m
Jun 30 2022	n/a	n/a	-JP¥224m
Mar 31 2022	n/a	n/a	JP¥100m
Dec 31 2021	JP¥231m	JP¥65m	JP¥1b
Sep 30 2021	n/a	n/a	JP¥1b
Jun 30 2021	n/a	n/a	JP¥1b
Mar 31 2021	n/a	n/a	JP¥1b
Dec 31 2020	JP¥157m	JP¥53m	JP¥1b
Sep 30 2020	n/a	n/a	-JP¥2b
Jun 30 2020	n/a	n/a	-JP¥1b
Mar 31 2020	n/a	n/a	-JP¥332m
Dec 31 2019	JP¥101m	JP¥40m	JP¥1b

Compensación vs. Mercado: Datos insuficientes para determinar si la compensación total de Chris es razonable en comparación con empresas de tamaño similar en el mercado German.

Compensación vs. Ingresos: La compensación de Chris ha aumentado mientras la empresa no es rentable.

CEO

Chris Cargill (40 yo)

2.7yrs

Permanencia

JP¥292,000,000

Compensación

Mr. Christopher Cargill, also known as Chris, serves as Representative Executive Officer, President, Chief Executive Officer and Director at Nxera Pharma Co., Ltd. (formerly known as Sosei Group Corporatio...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Shinichi Tamura	Founder & Chairman of the Board	19.4yrs	JP¥332.00m	0.66% € 4.2m
Christopher Cargill	Representative Executive Officer	2.7yrs	JP¥292.00m	0.046% € 292.7k
Hironoshin Nomura	Executive Officer	2.7yrs	sin datos	0.0016% € 9.8k
Toshihiro Maeda	Executive VP & COO	less than a year	sin datos	sin datos
Kieran Johnson	Executive Officer	2.7yrs	sin datos	0.0077% € 48.5k
Kazuhiko Yoshizumi	Executive Officer	6.8yrs	sin datos	0.0093% € 58.6k
Shinichiro Nishishita	VP of Investor Relations & Head of Regulatory Disclosures	no data	sin datos	sin datos
Stacey Southall	Associate Director & Head of Biophysics	no data	sin datos	sin datos
Candelle Chong	Executive Officer	1.7yrs	sin datos	0.0063% € 40.0k
Patrick Branch	Head of Business Development for Japan and the APAC region	less than a year	sin datos	sin datos
Makoto Sugita	President of Nxera Pharma Japan & Exe Officer	less than a year	sin datos	sin datos
Matthew Barnes	Hd. of Drug Disc. & UK R&D	2.7yrs	sin datos	0.0031% € 19.6k

2.7yrs

Permanencia media

48yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de JSS se considera experimentado (2.7 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Shinichi Tamura	Founder & Chairman of the Board	19.4yrs	JP¥332.00m	0.66% € 4.2m
Christopher Cargill	Representative Executive Officer	2.7yrs	JP¥292.00m	0.046% € 292.7k
Malcolm Weir	Member of Scientific Advisory Board	1.2yrs	JP¥134.00m	sin datos
Rolf Kristian Berndtson Soderstrom	Independent External Director	4.7yrs	sin datos	0.016% € 100.5k
Tomohiro Tohyama	Independent External Director	13.4yrs	sin datos	0.057% € 359.9k
Noriaki Nagai	External Independent Director	5.7yrs	sin datos	0.038% € 239.8k
Kuniaki Kaga	Independent External Director	6.4yrs	sin datos	0.040% € 249.9k
David Roblin	Independent External Director	6.4yrs	sin datos	0.0073% € 45.9k
Paul Leeson	Member of Scientific Advisory Board	no data	sin datos	sin datos
Peter Bernstein	Member of Scientific Advisory Board	no data	sin datos	sin datos
Richard Henderson	Member of Scientific Advisory Board	no data	sin datos	sin datos
Miwa Seki	External Independent Director	2.7yrs	sin datos	0.013% € 79.1k

5.7yrs

Permanencia media

66yo

Promedio de edad

Junta con experiencia: La junta directiva de JSS se considera experimentada (5.7 años de antigüedad promedio).

Nxera Pharma Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Nxera Pharma Co., Ltd. Appoints Makoto Sugita as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer of Nxera Pharma

Nxera Pharma Appoints Patrick Branch as Head of Business Development for Japan and APAC

Sosei Group Corporation, Annual General Meeting, Mar 27, 2024

Sosei Group Corporation Appoints Toshihiro Maeda as Chief Operating Officer

Sosei Group Corporation, Annual General Meeting, Mar 23, 2023

Sosei Group Corporation, Annual General Meeting, Mar 24, 2022

Recent updates

Third quarter 2024 earnings released: EPS: JP¥13.35 (vs JP¥59.82 loss in 3Q 2023)

Nxera Pharma Co., Ltd. Appoints Makoto Sugita as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer of Nxera Pharma

Nxera Pharma Co., Ltd. to Report Q3, 2024 Results on Nov 01, 2024

New minor risk - Share price stability

Second quarter 2024 earnings released: JP¥15.86 loss per share (vs JP¥8.01 loss in 2Q 2023)

Nxera Pharma Co., Ltd. to Report Q2, 2024 Results on Aug 09, 2024

First quarter 2024 earnings released: JP¥36.68 loss per share (vs JP¥17.11 loss in 1Q 2023)

Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568

Nxera Pharma Appoints Patrick Branch as Head of Business Development for Japan and APAC

Sosei Group Corporation Doses First Subject in a Phase 1 Trial Evaluating its Novel EP4 Receptor Agonist, HTL0033744 (HTL'744) for the Treatment of Inflammatory Bowel Disease

Sosei Group Corporation to Report Q1, 2024 Results on May 09, 2024

Now 22% undervalued after recent price drop

Full year 2023 earnings released: JP¥87.17 loss per share (vs JP¥4.67 profit in FY 2022)

Sosei Group Corporation, Annual General Meeting, Mar 27, 2024

New minor risk - Share price stability

Sosei Group Corporation Appoints Toshihiro Maeda as Chief Operating Officer

New minor risk - Shareholder dilution

Sosei Group Corporation Announces Marketing Approval for PIVLAZ (Clazosentan Sodium) 150 Mg in South Korea

Sosei Group Corporation to Report Fiscal Year 2023 Results on Feb 13, 2024

New major risk - Financial position

Idorsia Pharmaceuticals Japan Ltd. Submits New Drug Application to the Japanese Pharmaceuticals and Medical Devices Agency for the Approval of Daridorexant

Sosei Group Corporation to Report Q3, 2023 Results on Nov 10, 2023

Sosei Heptares and Cancer Research UK Announce the Dosing of the First Patient in a Phase I/IIa Trial with Cancer Immunotherapy Drug HTL0039732

Second quarter 2023 earnings released: JP¥8.01 loss per share (vs JP¥17.95 loss in 2Q 2022)

Sosei Group Corporation (TSE:4565) entered into an agreement to acquire Idorsia Pharmaceuticals Japan Ltd/Idorsia Pharmaceuticals Korea Co., Ltd from Idorsia Ltd (SWX:IDIA) for JPY 65 billion.

Sosei Heptares Doses First Subject in Phase I Trial with HTL0048149, a First-in-Class GPR52 Agonist for Schizophrenia

New minor risk - Share price stability

Sosei Group Corporation to Report Q2, 2023 Results on Aug 04, 2023

First quarter 2023 earnings released: JP¥17.11 loss per share (vs JP¥25.39 loss in 1Q 2022)

Now 22% undervalued

Full year 2022 earnings released: EPS: JP¥4.67 (vs JP¥12.53 in FY 2021)

Full year 2022 earnings released: EPS: JP¥4.67 (vs JP¥12.53 in FY 2021)

Sosei Group Corporation, Annual General Meeting, Mar 23, 2023

Sosei Group Corporation to Report Fiscal Year 2022 Results on Feb 14, 2023

Third quarter 2022 earnings released: EPS: JP¥3.82 (vs JP¥5.80 in 3Q 2021)

Third quarter 2022 earnings released: EPS: JP¥3.82 (vs JP¥5.80 in 3Q 2021)

Sosei Group Corporation to Report Q3, 2022 Results on Nov 11, 2022

Second quarter 2022 earnings released: JP¥17.95 loss per share (vs JP¥14.11 loss in 2Q 2021)

Sosei Heptares' Oral, Selective M4 Receptor Agonist Advancing into Phase 2 Clinical Development Under Multi-Program Collaboration with Neurocrine Biosciences

Cancer Research UK and Sosei Heptares Signs Agreement to Advance Cancer Immunotherapy Candidate into Clinical Trials

Sosei Group Corporation to Report Q2, 2022 Results on Aug 10, 2022

First quarter 2022 earnings released: JP¥25.39 loss per share (vs JP¥14.28 loss in 1Q 2021)

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Sosei Group Corporation, Annual General Meeting, Mar 24, 2022

Sosei Heptares Receives Grant Funding from Wellcome to Advance the Development of Potent, Differentiated Oral Anti-Viral Small Molecules to Treat COVID-19

Third quarter 2021 earnings released: EPS JP¥5.80 (vs JP¥5.94 in 3Q 2020)

Second quarter 2021 earnings released: JP¥14.11 loss per share (vs JP¥17.76 loss in 2Q 2020)

High number of new directors

Sosei Heptares Initiates Phase 1 Trial With Novel Small-Molecule CGRP Antagonist Under Collaboration With Biohaven

Sosei Group Corporation Provides Update of Their Strategic Multi-Target Drug Discovery Collaboration with Pfizer

First quarter 2021 earnings released: JP¥14.28 loss per share (vs JP¥9.68 loss in 1Q 2020)

Full year 2020 earnings released: EPS JP¥18.78 (vs JP¥18.69 in FY 2019)

Sosei Group Corporation to Report Q1, 2021 Results on May 12, 2021

Full year 2020 earnings released: EPS JP¥18.78 (vs JP¥18.69 in FY 2019)

Revenue misses expectations

Sosei Group Corporation, Annual General Meeting, Mar 24, 2021

Sosei Heptares to Explore Structure-Based Drug Discovery (SBDD) Approaches to Ion Channels Through Strategic Technology Collaboration with Metrion Biosciences

Sosei Heptares and PharmEnable Enter Technology Collaboration for AI-Driven Drug Discovery Against Challenging GPCR Target

New 90-day high: €14.40

Sosei Heptares to Regain Worldwide Rights to Muscarinic Agonist Programs

Sosei Group Corporation's Brand Sosei Heptares and Captor Therapeutics SA Enter Strategic Technology Collaboration Focused on Targeted GPCR Degradation as Novel Approach for Drug Design

New 90-day high: €13.50

Sosei Group Corporation to Report Fiscal Year 2020 Results on Feb 12, 2021

Sosei Group Corporation and Biohaven Pharmaceutical Holding Company Ltd. Enter Global Collaboration and License Agreement to Advance Novel Small-Molecule CGRP Antagonist Portfolio

Sosei Group Corporation Announces Progress Update for Its R&D Program Focused on the Design and Development of Novel Drugs Targeting the SARS-CoV-2 Coronavirus and to Treat COVID-19

Third quarter 2020 earnings released: EPS JP¥5.93

New 90-day high: €11.30

Sosei Heptares Announces a Second Novel Drug Candidate from its Multi-Target Drug Discovery Collaboration with Pfizer Starts Clinical Trials

Sosei Group Corporation to Report Q3, 2020 Results on Nov 11, 2020